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Dementia With Lewy Bodies
A Clinicopathologic Series of False-positive Cases
Leonie J.M. Vergouw, MD,* Luca P. Marler, MD,* Netherlands Brain Bank,†
Wilma D.J. van de Berg, PhD,‡ Annemieke J.M. Rozemuller, PhD,§∥
and Frank Jan de Jong, PhD*
Abstract: Diagnosing dementia with Lewy bodies (DLB) is chal-
lenging as symptoms are heterogenous and not specific to the disease.
Here we present a clinicopathologic series of false-positive DLB
cases. Patients were enrolled retrospectively from the Netherlands
Brain Bank when they met the clinical criteria of probable DLB, but
with a pathologic diagnosis other than DLB or Parkinson’s disease
dementia. Twenty-two false-positive cases were selected. Alzheimer
disease with or without copathology was the most common (64%)
pathologic diagnosis. Other pathologic diagnoses, such as fronto-
temporal dementia, multiple-system atrophy, Creutzfeldt-Jakob dis-
ease, and autoimmune encephalitis, were also encountered. Atypical
clinical signs for DLB were present in almost half of the cases and
could be a trigger to consider other diagnoses than DLB. Additional
diagnostic examinations, feedback of pathologic diagnosis, and the
creation of a set of clinical features that are indicative of other con-
ditions, could reduce the amount of false-positive DLB cases.
Key Words: dementia with Lewy bodies, false-positive cases, path-
ology, atypical clinical signs
(Alzheimer Dis Assoc Disord 2020;34:178–182)
D ementia with Lewy bodies (DLB) is one of the mostcommon types of dementia in the elderly1 and is patho-
logically characterized by cortical Lewy bodies and Lewy
neurites.2 Clinical symptoms include progressive cognitive
decline, parkinsonism, visual hallucinations, fluctuating cogni-
tion, and REM sleep behavior disorders (RBD).2 Often, there
is a large heterogeneity among DLB patients in their clinical
presentation, making it rather difficult to determine a correct
diagnosis. Furthermore, symptoms are not specific to the dis-
ease, which leads to many DLB cases being missed or
misdiagnosed.2 As DLB has a serious impact on quality of life
and disease management is complex, an early and correct
diagnosis is very important.2
The clinical criteria of DLB have been updated several
times to improve diagnostic accuracy. A recent review by
Rizzo et al,3 shows an increased sensitivity of the 2005 clinical
criteria in comparison with the 1996 clinical criteria, despite a
decreased specificity. This means that false-positive cases may
be encountered more frequently when using the clinical cri-
teria of 2005. The diagnostic accuracy of the clinical criteria
of 2017 is not yet known.
In this study, we focused on false-positive DLB cases
(DLB mimics) to increase our understanding of their
occurrence and causes thereof.
METHODS AND RESULTS
We collected all clinical and pathologic records in which the
word “Lewy” was mentioned of patients who donated their
brains to the Netherlands Brain Bank (NBB; www.brainbank.nl)
between 1987 and 2016. Two medical doctors (L.P.M. and L.J.
M.V.) reviewed the data and included all patients who met the
clinical criteria of probable DLB2 retrospectively. Symptoms
were only considered present if literally mentioned or clearly
described. Symptoms in all stages of the disease were considered.
Mimics were selected on the basis of a pathologic diagnosis other
than DLB or Parkinson’s disease dementia (low probability that
the clinical syndrome was related to Lewy pathology2). All
patients or their representatives signed informed consents for
brain autopsy and the use of their brain tissue and medical
records for research purposes. All procedures of the NBB were
approved by the medical ethical committee of VU University
Medical Center (Amsterdam UMC, Amsterdam).
Of the 80 patients who met the clinical criteria, 58 patients
had a high or intermediate probability that the clinical syndrome
was related to Lewy pathology, leaving 22 DLB mimics. The
mimics had a mean age of onset of 67.1±11.8 years, a mean
disease duration of 6.2±3.2 years, and 55% were male individ-
uals. Overall, 82% of the mimics presented with cognitive
decline. Parkinsonism, visual hallucinations, and fluctuations
were present in 73%, 86%, and 77% of the mimics, respectively.
Magnetic resonance imaging (MRI) scan was performed in 59%
(no conclusive results), cerebrospinal fluid (CSF) analysis in 14%,
dopamine transporter imaging in 9% (no abnormal findings),
and polysomnography in none of the mimics. Atypical signs
were present during life in 45% of the mimics (Table 1).
A pathologic diagnosis of pure Alzheimer disease (AD)
(n= 7) or AD with copathology (n= 7) was observed most
often, followed by frontotemporal dementia (FTD) (n= 2)
and other neurodegenerative diseases [multiple-system
atrophy (MSA), Creutzfeldt-Jakob disease (CJD), and neu-
rofilament inclusion body disease, n= 1 each] and non-
neurodegenerative diseases [autoimmune encephalitis (AIE),
glioblastoma, and old contusion, n= 1 each] (Table 1).
Pure AD
Severe AD pathology [Braak neurofibrillary tangles
(NFT)> 4; CERAD C]4 without copathology was seen in
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TABLE 1. Patients’ Characteristics According to Pathologic Diagnosis
Pure AD AD and Other Pathology
Patient I Patient II Patient III
Patient
IV Patient V
Patient
VI
Patient
VII Patient VIII Patient IX Patient X Patient XI
Pathologic
diagnosis
Pure AD (5C*) Pure AD (6C*) Pure AD (5C*) Pure AD
(5C*)
Pure AD
(6C*)
Pure AD
(6C*)
Pure AD
(5C*)
AD (3C*)
+vascular
damage
AD†+vascular
damage
AD (6B*)+Lewy
bodies in the
amygdala
AD (3C*)
+vascular
damage
Age of onset (y) 77 65 85 66 54 79 83 80 75 55 73
Sex F M M F M F F M F F F
Disease duration
from first
symptom (y)
4 6 2 4 10 12 8 3 4 7 10
Symptom of onset Cognitive decline Cognitive decline Cognitive decline Cognitive
decline
Cognitive
decline
Cognitive
decline
Cognitive
decline
Cognitive
decline
Cognitive decline Cognitive decline Cognitive
decline
Parkinsonism
(years after
onset)
Yes (3) No No Yes (2) No Yes (2) Yes (1) Yes (1) Yes (3) Yes (2) Yes (5)
Visual
hallucinations
(years after
onset)
Yes (2) Yes (3) Yes (1) No Yes (9) Yes (2) Yes (0) Yes (0) Yes (3) Yes (1) Yes (4)
Fluctuations
(years after
onset)
No Yes (5) Yes (1) Yes (2) Yes (5) Yes (2) No Yes (1) Yes (3) No Yes (6)
CSF NA NA NA NA NA NA NA NA NA Yes, AD profile NA
Positive DAT
imaging
NA NA NA NA NA NA NA NA NA NA NA
Atypical signs Early and
prominent
memory deficits
Early and
prominent
memory deficits
Early and
prominent
memory deficits
— — — — — Early and
prominent
memory deficits
— —
*Braak staging for neurofibrillary tangles and CERAD protocol for neuritic plaques.[4]
†No additional scoring available.
AD indicates Alzheimer disease; CJD, Creutzfeldt-Jakob disease; CSF, cerebrospinal fluid; CT, computed tomography; DAT, dopamine transporter; F, female; FTD, frontotemporal dementia; M, male; MSA,
multiple-system atrophy; NA, not available; PSP, progressive supranuclear palsy.
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TABLE 1. (Continued)
AD and Other Pathology FTD MSA CJD
Neurofilament
inclusion body
disease
Autoimmune
encephalitis Glioblastoma Old Contusion
Patient
XII
Patient
XIII
Patient
XIV Patient XV Patient XVI Patient XVII
Patient
XVIII Patient XIX Patient XX Patient XXI Patient XXII
AD (5C*)
+vascular
damage
AD (4B*)
+PSP
pathology
AD (6C*)
+atypical
Lewy
bodies
Progressive subcortical
gliosis
FTLD-TDP
type A
MSA Sporadic
variant CJD
Neurofilament
inclusion body
disease
Autoimmune
encephalitis
Glioblastoma Contusion frontal
and temporal
lobe
84 65 51 55 60 56 79 56 55 57 41
F M M F M M M M M F M
6 8 6 5 3 10 1 7 5 12 25
Cognitive
decline
Cognitive
decline
Cognitive
decline
Cognitive decline Parkinsonism Cognitive
decline
Parkinsonism Cognitive decline Cognitive decline Cognitive
decline
Hallucinations
No Yes (7) No Yes (1) Yes (0) Yes (7) Yes (0) Yes (5) Yes (2/3) No Yes (25)
Yes (2) Yes (5) Yes (2) Yes (2) No Yes (4) Yes (0) No Yes (3/4) Yes (0) Yes (0)
Yes (3) No Yes (2) No Yes (2) Yes (7) Yes (0) Yes (5) Yes (2/3) Yes (0) Yes (25)
NA NA NA NA Yes, amyloid
and tau not
tested
NA NA NA Yes with lymphocytic
reaction
NA NA
NA NA NA NA NA NA No NA No NA NA
— — — Early and prominent
behavioral changes;
hypoperfusion in frontal
lobes on SPECT imaging
— Early and
prominent
autonomic
nervous system
complaints
Short disease
duration
Positive family
history; frontal
hypoperfusion on
SPECT imaging
Early and prominent
psychiatric and
behavioral problems;
lymphocytic reaction in
CSF
— Early and
prominent
behavioral
changes; long
disease duration
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7 patients. Clinical signs that were atypical for DLB were
early and prominent memory deficits in patients I to III.
AD and Other Pathology
Intermediate or severe AD pathology (Braak NFT≥ 3;
CERAD≥B) with other pathology, for example, Lewy
bodies or vascular damage, was seen in 7 patients. Atypical
signs were early and prominent memory deficits in patient IX.
FTD
In patient XV, slight frontal atrophy, ballooned neu-
rons, and subcortical gliosis were present, but no Pick bodies
were found. Atypical signs were behavioral changes early in
the disease course and hypoperfusion of the frontal lobes on
SPECT imaging. In patient XVI, striatal atrophy and TDP-
43-positive inclusions and no NFT were found.
MSA
Severe neuronal loss in the substantia nigra, the puta-
men and pallidum, and glial cytoplasmic α-synuclein-
positive inclusions were observed in patient XVII. Signs that
were atypical for DLB were severe autonomic dysfunction
early in the disease course and dementia after 7 years of
symptom onset.
CJD
The brain of patient XVIII showed severe spongiform
degeneration with vacuolation, PrP depositions, Kuru pla-
ques, and prion plaques. A sign that was atypical for DLB
was a disease course of 1 year.
Neurofilament Inclusion Body Disease
Large, sometimes target-like neuronal inclusions localized
in the cortical gray matter and the spinal cord were seen in
patient XIX. In addition, this patient had a glioblastoma at
autopsy, not seen on an MRI scan 1 year earlier. Atypical signs
in this patient were a family history of neurofilament inclusion
body disease and frontal hypoperfusion on SPECT imaging.
AIE
Lymphocytic infiltrates and extensive loss and gliosis of,
among others, the hippocampi, amygdala, and basal ganglia,
were observed in patient XX. Clinical signs that were atypical
for DLB were severe depression, catatonia and behavioral
problems, and a lymphocytic reaction in the CSF.
Glioblastoma
In patient XXI tumorous tissue was observed in the left
temporal lobe composed of atypical glial cells, with con-
siderable polymorphia, including multinucleated glial cells
and necrosis.
Old Contusion
In patient XXII, 2 cortical defects with gliosis and
ferruginous pigment were seen in the frontal and temporal
lobe. Atypical signs for DLB were prominent behavioral
changes at the age of 41 and a disease duration of 25 years.
DISCUSSION
We found 22 mimics in a population of 80 patients who
retrospectively met the clinical criteria of DLB. The majority
(87%) of the mimics had another neurodegenerative disease,
which was most often AD or AD with copathology (64%).
Atypical clinical signs for DLB were observed in 10 mimics
and included atypical symptoms, atypical results of additional
examinations, an atypical family history, and an atypical
disease duration. These atypical signs could be a trigger to
consider other diagnoses than DLB.
The amount of mimics in our population (28%) is
slightly higher than has been shown in a recent study on the
accuracy of the 2005 clinical criteria for the diagnosis of
DLB.5 This study reported a mimic frequency of 21% in 14
clinically diagnosed probable DLB patients. Differences
between this study and our study include study design
(prospective study vs. retrospective study), clinical criteria
(2005 vs. 2017), and sample size (3 mimics vs. 22 mimics).
Similar to our study, a pathologic diagnosis of AD was most
often observed.
In our study, approximately half of the mimics had
atypical signs during life. Atypical symptoms included
prominent memory and behavioral, psychiatric, or auto-
nomic nervous system complaints early in the disease
course. When these symptoms are present, other diagnoses
such as AD, FTD, AIE, or MSA should be considered.
Dopamine transporter imaging is one of the best examina-
tions to differentiate between DLB and AD.6 An MRI scan
or FDG-PET scan are often used to differentiate between
DLB and FTD.7 Measuring autoantibodies in serum and/or
CSF and an MRI scan are important to differentiate
between DLB and AIE.8 The diagnosis of MSA is based on
clinical symptoms, but an MRI scan might be useful to
differentiate between DLB and MSA.9 Atypical results of
additional examinations included frontal hypoperfusion on
SPECT imaging. When frontal hypoperfusion is present,
FTD should especially be considered.7 Furthermore, an
atypical family history with multiple family members with
proven neurofilament inclusion body disease was observed.
If a patient has a similar clinical presentation as his family
members, it deserves preference to consider this diagnosis
until it can be excluded. At last, a disease duration of 1 year
and > 25 years were seen, which is atypical for DLB (mean
survival time in DLB: 6.1± 4.2 y).10 The mean survival time
of CJD is 5 months11 and should be considered when the
patient presents with a very rapidly progressive disease.
The main limitation of this study is its retrospective
nature. Specific clinical information, such as the presence of
fluctuations or RBD, were sometimes missing, and addi-
tional examinations were scarcely performed. Probable
DLB patients may, therefore, be missed, and the total
amount of probable DLB patients may be higher. This
could have led to a slightly different DLB population in this
study in comparison with the DLB population seen today,
in which clinical signs are often better recognized and where
additional examinations are increasingly performed. Fur-
thermore, selection bias may have been introduced by the
preference of patients to register as brain donors when the
diagnosis during life was not clear. This may have led to a
higher percentage of DLB mimics in this study.
This study shows that DLB mimics occur relatively
often, especially those with a pathologic diagnosis of AD.
Additional diagnostic examinations and feedback of
pathologic diagnosis to clinicians is very important to
reduce the amount of DLB mimics. Furthermore, the spe-
cificity of the clinical criteria of DLB could be improved by
including a set of clinical features that are indicative of other
conditions and justify further investigation.
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